Q-omics provides the consensus-scored LRRIQ4 profile across patient tissues and cancer cell-line models. LRRIQ4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LRRIQ4 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, LRRIQ4 RNA expression shows 15,586 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCEC, THCA, and KIRP as cancer lineages where LRRIQ4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRIQ4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRIQ4 survival associations across molecular data types. LRRIQ4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRIQ4 RNA expression–survival associations across cancer types. High LRRIQ4 expression shows unfavorable associations in UCEC, KICH and GBM, but favorable associations in HNSC, UVM and UCS. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LRRIQ4 RNA expression.
This table summarizes LRRIQ4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LRRIQ4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRIQ4 shows lower tumor expression in THCA and higher tumor expression in BLCA, BRCA, LUAD, HNSC and STAD. The THCA box plot shows higher LRRIQ4 RNA expression in normal versus tumor tissue (log2 FC = −0.163, t-test p < 0.001).
This table shows molecular features associated with LRRIQ4 in patient tissues and cancer cell lines. In patient samples, LRRIQ4 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRIQ4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
